Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › ATTAIN-1

ATTAIN-1

Orforglipron · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
Orforglipron
Population
obesity
Official title
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Sponsor
Eli Lilly and Company
Phase
3
Registry status
active not recruiting · 2023-06 → 2025-07
Participants
3127
Duration
72 weeks
Registry
NCT05869903

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
orforglipron 36 mgobesity723127−12.4 % vs −0.9 %
Δ −11.5 pp
−11.2 % vs −2.1 %
Δ −9.1 pp
—10.3 vs 2.724.4 vs 29.9——3.8 vs 4.9—verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (5)
  • orforglipron 36 mg · weight_eff · Figure 1B (garbled text; arm mapping inferred from ETDs)
    −7.8 −12.4 −0.9 −9.3 ETD, −11.5 percentage points (95% CI, −12.3 to −10.6) ETD, −8.4 percentage points (95% CI, −9.2 to −7.6) ETD, −6.9 percentage points
  • orforglipron 36 mg · weight_tp · Table 2
    −7.5 (−8.2 to −6.8) −8.4 (−9.1 to −7.7) −11.2 (−12.0 to −10.4) −2.1 (−2.8 to −1.4)
  • orforglipron 36 mg · ae_dc · Table 4
    Any adverse event 38 (5.3) 57 (7.9) 75 (10.3) 26 (2.7) 196 (6.3)
  • orforglipron 36 mg · disc_any · Results, Patients; computed from 552 (75.6%) of 730 continui
    the percentage of patients who discontinued treatment for any reason was 25.0% (21.9 to 24.4% in the orforglipron groups and 29.9% in the placebo group)
  • orforglipron 36 mg · sae · Table 4
    Serious adverse event 40 (5.5) 39 (5.4) 28 (3.8) 46 (4.9) 153 (4.9)

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: ATTAIN-1. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/attain-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.